Literature DB >> 9776014

Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions.

M de Sèze1, L Wiart, P A Joseph, J P Dosque, J M Mazaux, M Barat.   

Abstract

The aim of this study was to investigate the efficacy and tolerance of capsaicin, a neurotoxin for C-fiber afferents, applied intravesically in the treatment of detrusor hyperreflexia. Eleven male and nine female patients who had spinal cord lesions caused by multiple sclerosis (12) or trauma (eight) resulting in detrusor hyperreflexia with urge incontinence and pollakiuria were randomized to receive one intravesical instillation of either 30 mg capsaicin in 100 ml 30% ethanol or 100 ml 30% ethanol alone. The patients were evaluated clinically (voiding diary) and urodynamically (maximum cystometric capacity, maximum detrusor pressure, first and normal desire to void) before and 30 days after the instillation. On day 30, the 10 patients who received capsaicin had significant decreases in 24-h voiding frequency from 9.3+/-6.1 to 6.7+/-3.8 (P=0.016) and leakages from 3.9+/-1.6 to 0.6+/-0.8 (P=0.0008); their maximum cystometric capacity increased from 169+/-68 to 299+/-96 ml (P=0.01) and maximum detrusor pressure decreased from 77+/-24 to 53+/-27 cm H2O. There were no significant changes in the control group. In seven subjects in each group, instillation triggered immediate side effects (suprapubic pain, sensory urgency, flushes, hematuria, autonomic hyperreflexia) that resolved within 2 weeks. Intravesical capsaicin significantly improves clinical and urodynamic parameters of detrusor hyperreflexia in spinal cord-injured patients. Side effects are frequent, tolerable, and identical to those induced by 30% ethanol alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776014     DOI: 10.1002/(sici)1520-6777(1998)17:5<513::aid-nau7>3.0.co;2-g

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  18 in total

1.  Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity?

Authors:  Bernard T Haylen; Naven Chetty; Vanessa Logan; Serena Schulz; Louise Verity; Matthew Law; Jialun Zhou
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-07-06

Review 2.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

3.  Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC).

Authors:  Tony Y H Chen; Jacques Corcos; Michel Camel; Yves Ponsot; Le Mai Tu
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-04-08

Review 4.  Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.

Authors:  Oussama El Yazami Adli; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

Review 5.  Receptors, channels, and signalling in the urothelial sensory system in the bladder.

Authors:  Liana Merrill; Eric J Gonzalez; Beatrice M Girard; Margaret A Vizzard
Journal:  Nat Rev Urol       Date:  2016-03-01       Impact factor: 14.432

Review 6.  TRP channels in lower urinary tract dysfunction.

Authors:  J Franken; P Uvin; D De Ridder; T Voets
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 7.  Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects.

Authors:  Roderick MacDonald; Manoj Monga; Howard A Fink; Timothy J Wilt
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

Review 8.  TRPs in bladder diseases.

Authors:  Lori A Birder
Journal:  Biochim Biophys Acta       Date:  2007-04-20

Review 9.  Animal models in urological disease and sexual dysfunction.

Authors:  Gordon McMurray; James H Casey; Alasdair M Naylor
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 10.  Management of overactive bladder syndrome.

Authors:  Sushma Srikrishna; Dudley Robinson; Linda Cardozo; Maria Vella
Journal:  Postgrad Med J       Date:  2007-07       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.